Serum sclerostin in vascular calcification in CKD: a meta-analysis

References

• GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395:709–733.
   PubMed Web of Science ®Google Scholar
• Couser WG, Remuzzi G, Mendis S, et al. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80(12):1258–1270.
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154–2169.
   PubMed Web of Science ®Google Scholar
• London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18(9):1731–1740.
   PubMed Web of Science ®Google Scholar
• Braga PC, Alves MG, Rodrigues AS, et al. Mitochondrial pathophysiology on chronic kidney disease. Int J Mol Sci. 2022;23:1776.
   PubMedGoogle Scholar
• Kipourou K, O’Driscoll JM, Sharma R. Valvular heart disease in patients with chronic kidney disease. Eur Cardiol. 2022;17:e02.
   PubMed Web of Science ®Google Scholar
• Diemar SS, Dahl SS, West AS, et al. A systematic review of the circadian rhythm of bone markers in blood. Calcif Tissue Int. 2022;112(Suppl 1):1–22.
   PubMedGoogle Scholar
• Lems W, Miceli-Richard C, Haschka J, et al. Bone involvement in patients with spondyloarthropathies. Calcif Tissue Int. 2022;110(4):393–420.
   PubMed Web of Science ®Google Scholar
• Drueke TB. Hyperparathyroidism in chronic kidney disease. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.
   Google Scholar
• Mace ML, Egstrand S, Morevati M, et al. New insights to the crosstalk between vascular and bone tissue in chronic kidney disease-mineral and bone disorder. Metabolites. 2021;11:849.
   PubMed Web of Science ®Google Scholar
• Claes KJ, Viaene L, Heye S, et al. Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab. 2013;98(8):3221–3228.
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Goffin E, Meijers B, et al. Sclerostin serum levels and vascular calcification progression in prevalent renal transplant recipients. J Clin Endocrinol Metab. 2015;100(12):4669–4676.
   PubMed Web of Science ®Google Scholar
• Qureshi AR, Olauson H, Witasp A, et al. Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int. 2015;88(6):1356–1364.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The prisma 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   Google Scholar
• Wells G. The Newcastle Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analysis. Proceedings of the Third Symposium on Systematic Reviews. London: Oxford; 2000.
   Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.1. London: Cochrane Collaboration; 2020.
   Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• Viaene L, Behets GJ, Claes K, et al. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant. 2013;28(12):3024–3030.
   PubMed Web of Science ®Google Scholar
• Goncalves FL, Elias RM, dos Reis LM, et al. Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol. 2014;15:190.
   PubMed Web of Science ®Google Scholar
• Kanbay M, Siriopol D, Saglam M, et al. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab. 2014;99(10):E1854–1861.
   PubMed Web of Science ®Google Scholar
• Drechsler C, Evenepoel P, Vervloet MG, et al. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the necosad study. Nephrol Dial Transplant. 2015;30(2):288–293.
   PubMed Web of Science ®Google Scholar
• Morena M, Jaussent I, Dupuy AM, et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant. 2015;30(8):1345–1356.
   PubMed Web of Science ®Google Scholar
• Yang CY, Chang ZF, Chau YP, et al. Circulating wnt/beta-catenin signalling inhibitors and uraemic vascular calcifications. Nephrol Dial Transplant. 2015;30(8):1356–1363.
   PubMed Web of Science ®Google Scholar
• Jean G, Chazot C, Bresson E, et al. High serum sclerostin levels are associated with a better outcome in haemodialysis patients. Nephron. 2016;132(3):181–190.
   PubMed Web of Science ®Google Scholar
• Kirkpantur A, Balci M, Turkvatan A, et al. Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients. Nefrologia. 2016;36(1):24–32.
   PubMed Web of Science ®Google Scholar
• Lips L, de Roij van Zuijdewijn CLM, Ter Wee PM, et al. Serum sclerostin: relation with mortality and impact of hemodiafiltration. Nephrol Dial Transplant. 2017;32:1217–1223.
   PubMed Web of Science ®Google Scholar
• Wang XR, Yuan L, Zhang JJ, et al. Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3–5d. Nephrology (Carlton). 2017;22(4):286–292.
   PubMed Web of Science ®Google Scholar
• Jørgensen HS, Winther S, Dupont L, et al. Sclerostin is not associated with cardiovascular event or fracture in kidney transplantation candidates. Clin Nephrol. 2018;90(1):18–26.
   PubMed Web of Science ®Google Scholar
• Zhao B, Chen A, Wang H, et al. The relationship between sclerostin and carotid artery atherosclerosis in patients with stage 3–5 chronic kidney disease. Int Urol Nephrol. 2020;52(7):1329–1336.
   PubMed Web of Science ®Google Scholar
• Neto R, Pereira L, Magalhães J, et al. Low bone turnover is associated with plain x-ray vascular calcification in predialysis patients. PLoS One. 2021;16(10):e0258284.
   Web of Science ®Google Scholar
• National Kidney Foundation. K/doqi clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–S266.
   PubMed Web of Science ®Google Scholar
• Evans M, Lewis RD, Morgan AR, et al. A narrative review of chronic kidney disease in clinical practice: current challenges and future perspectives. Adv Ther. 2022;39(1):33–43.
   PubMed Web of Science ®Google Scholar
• Oluyombo R, Banjo Oguntade H, Soje M, et al. Obesity and ckd in sub-Saharan Africa: a narrative review. Kidney Med. 2022;4(2):100403.
   PubMedGoogle Scholar
• Kim JS, Hwang HS. Vascular calcification in chronic kidney disease: distinct features of pathogenesis and clinical implication. Korean Circ J. 2021;51(12):961–982.
   PubMed Web of Science ®Google Scholar
• Hernandez P, Whitty C, John Wardale R, et al. New insights into the location and form of sclerostin. Biochem Biophys Res Commun. 2014;446(4):1108–1113.
   PubMed Web of Science ®Google Scholar
• Weidauer SE, Schmieder P, Beerbaum M, et al. NMR structure of the Wnt modulator protein sclerostin. Biochem Biophys Res Commun. 2009;380(1):160–165.
   PubMed Web of Science ®Google Scholar
• Nguyen AT, Gomez D, Bell RD, et al. Smooth muscle cell plasticity: fact or fiction? Circ Res. 2013;112(1):17–22.
   PubMed Web of Science ®Google Scholar
• De Mare A, Maudsley S, Azmi A, et al. Sclerostin as regulatory molecule in vascular media calcification and the bone-vascular axis. Toxins (Basel). 2019;11:E428.
   PubMed Web of Science ®Google Scholar
• Woldt E, Terrand J, Mlih M, et al. The nuclear hormone receptor ppargamma counteracts vascular calcification by inhibiting wnt5a signalling in vascular smooth muscle cells. Nat Commun. 2012;3:1077.
   PubMed Web of Science ®Google Scholar
• Abedin M, Lim J, Tang TB, et al. N-3 fatty acids inhibit vascular calcification via the p38-mitogen-activated protein kinase and peroxisome proliferator-activated receptor-gamma pathways. Circ Res. 2006;98(6):727–729.
   PubMed Web of Science ®Google Scholar
• Ukita M, Yamaguchi T, Ohata N, et al. Sclerostin enhances adipocyte differentiation in 3t3-l1 cells. J Cell Biochem. 2016;117(6):1419–1428.
   PubMed Web of Science ®Google Scholar
• Koos R, Brandenburg V, Mahnken AH, et al. Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study. J Heart Valve Dis. 2013;22:317–325.
   PubMed Web of Science ®Google Scholar
• Brandenburg VM, Kramann R, Koos R, et al. Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol. 2013;14:219.
   PubMed Web of Science ®Google Scholar
• Zhu D, Mackenzie NC, Millan JL, et al. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PloS One. 2011;6(5):e19595.
   Web of Science ®Google Scholar
• Cejka D, Marculescu R, Kozakowski N, et al. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab. 2014;99(1):248–255.
   PubMed Web of Science ®Google Scholar
• Pelletier S, Confavreux CB, Haesebaert J, et al. Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients? Osteoporos Int. 2015;26(8):2165–2174.
   PubMed Web of Science ®Google Scholar
• Sabbagh Y, Graciolli FG, O'Brien S, et al. Repression of osteocyte wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res. 2012;27(8):1757–1772.
   PubMed Web of Science ®Google Scholar
• Novo-Rodriguez C, Garcia-Fontana B, Luna-Del Castillo JD, et al. Circulating levels of sclerostin are associated with cardiovascular mortality. PloS One. 2018;13(6):e0199504.
   PubMed Web of Science ®Google Scholar
• Vasiliadis ES, Evangelopoulos DS, Kaspiris A, et al. The role of sclerostin in bone diseases. J Clin Med. 2022;11:806.
   PubMed Web of Science ®Google Scholar